Store Operations and Growth - As of the end of Fiscal 2025, Shoe Carnival operated 426 stores across 35 states and Puerto Rico, consisting of 144 Shoe Station locations and 282 Shoe Carnival locations [15]. - Shoe Station bannered stores represented approximately 34% of the total store fleet at the end of Fiscal 2025, up from approximately 10% at the end of Fiscal 2024 [29]. - The company rebannered 101 stores in Fiscal 2025, including 73 Shoe Carnival stores and all 28 Rogan's stores [29]. - The company plans to rebanner approximately 21 stores during the first half of Fiscal 2026 to evaluate consumer demographics and marketing effectiveness [31]. - The company anticipates that over 90% of its store fleet will operate as Shoe Station stores by the end of Fiscal 2028 [91]. - The company expects no significant store closures over the next several years as it actively monitors its store portfolio [174]. - In Fiscal 2025, the company rebannered 101 stores into Shoe Station stores, with expectations that approximately 70 additional stores would be rebannered before Back-to-School in Fiscal 2026, leading to Shoe Station stores representing 51% of the current store fleet [196]. Financial Performance - In Fiscal 2025, Shoe Station achieved Net Sales growth of 2.7%, significantly outpacing Shoe Carnival banner Net Sales declines by 10.4 percentage points [30]. - Operating Income for Fiscal 2025 decreased by approximately $24.1 million compared to Fiscal 2024 due to costs associated with store closures and rebanner investments [34]. - Net Income for Fiscal 2025 was $52.3 million, or $1.90 per diluted share, down from $73.8 million, or $2.68 per diluted share in Fiscal 2024 [207]. - The company achieved a Gross Profit margin of 36.6% in Fiscal 2025, up 100 basis points from Fiscal 2024, driven by disciplined pricing and a favorable mix shift towards higher income customers [210]. - Comparable stores Net Sales declined 5.6% in Fiscal 2025, with Shoe Station growing low single digits while Shoe Carnival experienced high-single digit declines [209]. - Net Sales from the Shoe Station banner grew from $99.9 million in Fiscal 2022 to $236.7 million in Fiscal 2025, with growth rates of 4.5% in Fiscal 2023, 6.4% in Fiscal 2024, and 2.7% in Fiscal 2025 [202]. - Net Sales from the Shoe Carnival banner declined from $1.161 billion in Fiscal 2022 to $821.8 million in Fiscal 2025, with declines of 7.8% in Fiscal 2023, 5.7% in Fiscal 2024, and 7.7% in Fiscal 2025 [203]. Capital Expenditures and Investments - Capital expenditures supporting the rebanner initiative totaled approximately $37.1 million in Fiscal 2025, with an anticipated additional $5 to $7 million in Fiscal 2026 [34]. - The company plans to invest in omnichannel initiatives, requiring substantial technology investments to improve operational systems and manage employee training [117]. - The company requires significant funds to implement its business strategy and may face liquidity risks if it fails to generate sufficient cash flow [149]. Customer Engagement and Sales Channels - Purchases from Shoe Perks members accounted for approximately 78% of comparable stores net sales in Fiscal 2025 [47]. - The company’s Shoe Perks customer loyalty program accounts for approximately 78% of comparable stores Net Sales in Fiscal 2025 [116]. - E-commerce sales represented approximately 10% of merchandise sales in both Fiscal 2025 and Fiscal 2024 [39]. - E-commerce sales are a significant channel, with fulfillment primarily from store locations and the Evansville distribution center, which is critical for operations [113]. Supply Chain and Distribution - The company's distribution center in Evansville received 97% of merchandise during Fiscal 2025, utilizing a paperless process for efficiency [54]. - The company operates a single distribution center in Evansville, Indiana, making it vulnerable to disruptions that could significantly impact merchandise delivery [122]. - The company has a distribution center in Evansville, Indiana, with a current capacity to support approximately 470 stores, expandable to 650 stores [176]. Employee and Workplace Culture - As of Fiscal 2025, the company had approximately 5,000 employees, with 2,700 employed part-time, and none represented by a labor union [75]. - The leadership team averages 22 years of employment with the company, indicating strong retention and internal promotion practices [66]. - The company’s employee-centric culture has led to increased retention of key talent, with 67% of district managers employed for over 20 years [65]. Risks and Challenges - The retail footwear industry is highly competitive, with significant pressure on gross profit margins due to promotional activities from competitors [96]. - The company faces risks related to consumer spending, which could adversely affect sales and promotional strategies [97]. - Recent tariffs on imported footwear from countries like China and Vietnam have created uncertainty and potential disruptions in the supply chain [105]. - The company relies heavily on imported goods, with risks including disruptions from political unrest, shipping issues, and changes in trade policy [109]. - The company faces risks related to e-commerce operations, including reliance on third-party providers and potential cybersecurity threats [114]. - The company is exposed to physical and financial risks related to climate change, which could impact real estate availability and increase capital expenditures [140]. - The company faces compliance and litigation risks regarding the protection of customer and employee data, with potential fines and penalties for non-compliance [141]. - The company may not have adequate insurance coverage for all potential liabilities, which could adversely affect its financial condition [142]. - Financial market volatility could adversely affect the sources and costs of financing available to the company [150]. - The company is subject to periodic litigation and regulatory proceedings, which could divert management's attention and resources [143]. Corporate Governance - The proposed corporate name change to Shoe Station Group, Inc. reflects the Board's belief that the Shoe Station concept is the primary long-term growth vehicle [35]. - The company is controlled by principal shareholders who own approximately 31.7% of the outstanding common stock, potentially influencing management decisions [154]. - The company has a share repurchase program authorizing the purchase of up to $50 million of its common stock through December 31, 2026, but is not obligated to make any purchases [158]. - The company has implemented a risk-based cybersecurity framework to address threats and protect sensitive information [162]. - The company has not identified any material risks from cybersecurity threats as of January 31, 2026 [169].

IPO and Fundraising - The company completed its IPO on June 20, 2025, raising gross proceeds of $253 million from the sale of 25,300,000 units at $10.00 per unit, including 3,300,000 units from the underwriters' over-allotment option[130][135]. - The company also raised an additional $6.4 million from the private placement of 6,400,000 warrants at $1.00 per warrant, bringing total offering proceeds to approximately $259.4 million[130][136]. Financial Performance - As of December 31, 2025, the company reported a net income of $4,782,280, primarily due to an unrealized return on investments in the trust account amounting to $5,327,825[133]. - The company had cash of $764,902 and working capital of $664,220 as of December 31, 2025, indicating a need for further capital to pursue acquisition plans[125]. Trust Account and Use of Funds - The funds in the trust account, totaling $253 million, will be used to complete the initial business combination and are invested in U.S. government treasury bills or money market funds[138][139]. - The company expects to incur approximately $150,000 for legal and accounting expenses related to business combinations and $320,000 for administrative services, among other costs[142]. Operational Status - The company has not engaged in any operations or generated revenues to date, with all activities focused on organizational efforts and evaluating potential acquisition targets[132]. Risks and Challenges - The company may face significant dilution of equity interests if additional shares or debt are issued during the business combination process[124]. - The SEC's 2024 SPAC Rules, effective July 1, 2024, may impact the company's ability to negotiate and complete its initial business combination, potentially increasing costs and time[127]. - The company has not borrowed any amounts under a promissory note with its sponsor as of December 31, 2025, indicating reliance on IPO proceeds for liquidity[134].

Clinical Development and Trials - Clinical candidate mipletamig is currently being evaluated in the RAINIER trial for frontline acute myelogenous leukemia (AML) in combination with standard care, showing a strong remission rate across all cohorts[16]. - In the Phase 1b dose expansion trial, mipletamig demonstrated an 82% composite clinical remission rate and a 73% complete remission rate in venetoclax-naïve patients[31]. - The RAINIER trial includes up to 51 patients treated across five dose levels, with the trial expected to conclude in the second half of 2026[37]. - Approximately 49% of evaluable monotherapy patients in the dose escalation trial experienced clinical benefit, with 36% showing substantial AML blast reductions[33]. - ALG.APV-527 Phase 1 trial completed with 10 of 17 efficacy evaluable patients (59%) achieving stable disease, including one breast cancer patient with stable disease for over 11 months[48]. - The company completed a Phase 1b dose expansion clinical trial with mipletamig in 2023 and initiated a Phase 1b/2 study in August 2024 to optimize dosing[195]. - The company may face delays in clinical trials due to challenges in patient enrollment, which could increase development costs and delay commercial launch[205]. - Serious adverse events or undesirable side effects from product candidates could lead to regulatory interruptions or the need to limit development[207]. Product Safety and Efficacy - Mipletamig's differentiated safety profile is attributed to the proprietary CRIS-7 binding domain, with most cytokine release syndrome cases being mild and manageable[34]. - No severe liver toxicity observed in the ALG.APV-527 trial, indicating a favorable safety profile[44]. - ALG.APV-527 demonstrated biological activity with measurable levels detected in all evaluable patients, proportional to the administered dose[48]. - Serious adverse events (SAEs) may lead to the abandonment or limitation of product candidates to narrower uses or subpopulations[208]. - Regulatory authorities could require additional clinical trials or abandon research efforts for other product candidates[210]. - Commercialization costs may substantially increase due to adverse events, delaying revenue generation from product sales[209]. - Regulatory authorities may impose additional warnings on product labels or restrict distribution and use[210]. - The company could face lawsuits and liability for harm caused to patients[210]. - The company's reputation may suffer due to adverse events associated with its products[210]. Competitive Landscape - The company faces intense competition from both domestic and international producers of immune oncology products, necessitating ongoing innovation and development[70]. - Mipletamig is expected to compete with various agents targeting CD123 and non-CD123 for AML treatment, with notable competitors including Affimed, ImmunoGen, and Sanofi[71]. - ALG.APV-527 targets 4-1BB in a bispecific format and faces competition from other bispecifics and anti-drug conjugates currently in preclinical and clinical development[72]. - The oncology market presents significant competition from major companies such as AstraZeneca, Bristol Myers Squibb, and Gilead Sciences[73]. - The company holds a strong position in the bispecific oncology space, supported by competitive safety and efficacy data compared to industry benchmarks[58]. Financial Position and Risks - For the year ended December 31, 2025, the company reported a net loss of $26.0 million and an accumulated deficit of $275.1 million[162]. - As of December 31, 2025, the company had cash and cash equivalents amounting to $21.6 million, indicating a need for additional funding to support ongoing clinical development and marketing activities[164]. - The company faces significant risks, including the potential for delisting from the Nasdaq Capital Market if it fails to meet listing requirements, which could adversely affect stock liquidity and market price[161]. - The company has a history of operating losses and may not achieve profitability in the future, which raises substantial doubt about its ability to continue as a going concern[163]. - The company anticipates ongoing annual net operating losses as it expands efforts to discover and commercialize immunotherapeutic candidates[162]. - Macroeconomic conditions, including inflation and market volatility, could significantly impact the company's capital requirements and ability to raise funds[168]. - The company may face limitations on its ability to utilize net operating loss carryforwards due to potential ownership changes, which could adversely affect its financial condition and results of operations[190]. Intellectual Property and Collaboration - Aptevo's collaboration with Alligator Bioscience involves joint development of ALG.APV-527, with shared ownership of intellectual property and revenue[75][76]. - The Collaboration Agreement allows for opt-out options at specific development stages, impacting cost-sharing and commercialization rights[77]. - Aptevo employs a combination of patents, trademarks, and trade secrets to protect its intellectual property, focusing on significant markets[80][82]. - The ADAPTIR platform technology is protected through patents and trade secrets, with ongoing improvements and patent applications planned[86][89]. - Aptevo has pending patent applications for several therapeutic candidates, including APVO442, APVO603, and APVO711, which have been nationalized in various countries[95]. Regulatory Environment - Regulatory compliance is crucial for product development, requiring substantial time and financial resources for approvals in the U.S. and other countries[98]. - The FDA mandates a rigorous process for investigational new drug applications, including preclinical testing and clinical trial protocols[99][101]. - The FDA requires satisfactory completion of an inspection of manufacturing facilities to assess compliance with current Good Manufacturing Practices (cGMP) before approving a Biologics License Application (BLA)[103]. - Typically, two Phase 3 clinical trials are required by the FDA for product approval, which provide definitive statistical evidence of the efficacy and safety of the proposed product[105]. - The FDA aims to review and act on Priority Review submissions within six months, compared to a ten-month goal for Standard Review applications[117]. - The Prescription Drug User Fee Act (PDUFA) establishes a two-tiered review system, impacting the timeline for BLA approvals based on the severity of the condition being treated[117]. - The FDA may issue a Complete Response Letter (CRL) if an application does not provide an adequate basis for approval, detailing specific deficiencies that must be addressed[120]. - The FDA may require post-marketing commitment studies to collect long-term safety information after a product has been approved[105]. - The FDA may grant deferrals for submission of pediatric data under the Pediatric Research Equity Act (PREA) for certain indications[107]. - The FDA may impose conditions on approval, such as requiring a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of a product outweigh its risks[121]. - The FDA may refer applications to an advisory committee for review, especially for new active ingredients that have not been previously approved[118]. - The FDA may revoke the designation of a platform technology if it no longer meets the criteria for such designation, impacting the development and review process for related products[124]. Human Capital and Organizational Structure - As of December 31, 2025, the company employed 33 full-time and 3 contract personnel, indicating a focused team structure[144]. - The company emphasizes the importance of attracting and retaining qualified personnel through competitive compensation and comprehensive benefits[144]. - The principal executive offices are located at 2401 4th Ave., Suite 1050, Seattle, Washington 98121[145]. - The company promotes a culture of professionalism, respect, and accountability among its employees[146]. - The Board of Directors and executive team actively monitor human capital resources to ensure adherence to core values[147]. - The transition of leadership, with Marvin L. White becoming Executive Chair and Jeff Lamothe as President and CEO effective April 1, 2026, is critical for the company's future success[182].

Tax Attributes and Financial Impact - The company has substantial U.S. federal net operating loss (NOL) carryforwards as of December 31, 2025, which may be limited annually due to ownership change provisions [255]. - Some U.S. federal NOL carryforwards will begin to expire in 2028, while others have no expiration [255]. - The company believes it has undergone ownership changes in 2013, 2014, 2015, and 2021, which limits the utilization of pre-change NOL carryforwards [256]. - The company maintains a full valuation allowance for its net deferred tax assets as of December 31, 2025 [255]. - The company may face a reduction in tax attributes due to debt discharge resulting from the Prepackaged Chapter 11 Case, which could adversely affect future cash flow [259]. - U.S. federal income tax attributes subject to reduction include NOLs, general business credit carryovers, and foreign tax credit carryovers, potentially impacting financial performance [260]. - The company anticipates that the application of the 382(l)(5) Exception could lead to significant future cash tax savings, although there are complexities and uncertainties involved [261]. - Changes in tax laws, including the One Big Beautiful Bill Act enacted on July 4, 2025, could materially impact the company's financial condition and results of operations [258]. Environmental, Social, and Governance (ESG) Concerns - The company is subject to scrutiny regarding environmental, social, and governance (ESG) practices, which may incur costs and complexity [236]. - Failure to meet ESG expectations could negatively impact the company's reputation, customer retention, and access to capital [239]. Capital and Financing Risks - The company may need to seek additional debt or equity capital to fund operations and pursue business objectives, which may not be available on acceptable terms [240]. - Any additional debt financing could result in restrictive covenants that may hinder the company's ability to obtain further capital [241]. Market and Stock Performance - The lack of analyst coverage could decrease demand for the company's common stock, potentially leading to a decline in stock price and trading volume [251]. - Public guidance on expected operating and financial results is subject to uncertainties, and failure to meet such guidance may lead to a decline in stock price [270][272]. - Short selling practices may negatively impact the company's stock price, as short sellers may spread misinformation to create negative market momentum [273][274]. - Stockholder activism could disrupt business operations, incur significant expenses, and adversely affect stock price and management focus [275]. Operational Risks - The company is exposed to risks from natural disasters, geopolitical conflicts, and terrorism, which could disrupt operations and negatively impact financial results [263][265]. - Future acquisitions may divert management's attention and resources, potentially leading to dilution of stockholder value and operational disruptions [266][267]. - The company maintains insurance customary for its size, but there may be types of losses that are uninsured or inadequately covered, which could adversely affect financial condition [269].

Financial Performance - Total net revenue increased to $4.1 million for the year ended December 31, 2025, compared to $1.9 million in 2024, representing a 116% increase [276]. - Net loss decreased to $50.2 million for the year ended December 31, 2025, compared to a net loss of $60.7 million in 2024, a reduction of 17% [278]. - The company had an accumulated deficit of $400.8 million as of December 31, 2025 [293]. - The net loss for the year ended December 31, 2025, was $50.2 million, with net cash used in operating activities amounting to $22.2 million [304]. Revenue Sources - Laboratory Services revenue increased by $2.2 million, primarily from one existing customer, totaling approximately $4.0 million during 2025 [278]. - The company earned its first Kitted Products revenue of approximately $24,000 during 2025 [278]. - Total other income increased by $524,000, primarily from higher interest income due to increased cash balances [280]. Expenses - Cost of revenues increased by $697,000, primarily due to labor and overhead associated with Laboratory Services and Kitted Products inventory costs [278]. - Research and development expenses increased by $6.1 million to $15.9 million, a 62% increase, driven by laboratory supplies and professional fees [284]. - Sales and marketing expenses rose by $2.4 million to $6.34 million, a 61% increase, primarily due to increased personnel-related expenses and marketing activities [286]. - General and administrative expenses increased by $429,000 to $10.63 million, a 4% increase, mainly due to higher personnel-related expenses and stock-based compensation [287]. - Total research and development expenses for the year ended December 31, 2025, were $15.9 million, while sales and marketing expenses were $6.3 million, and general and administrative expenses were $10.6 million [304]. Strategic Partnerships and Developments - The company entered into a global strategic partnership with Bio-Rad for the development and commercialization of kitted transplant products [264]. - A clinical trial for GraftAssureDx began in 2025, with a data package submitted to the FDA on March 25, 2026, seeking marketing authorization [267]. - The company plans to expand its GraftAssure product offering into heart transplant rejection testing, supported by net proceeds from the February 2026 Offering [295]. - A global strategic partnership with Bio-Rad was established to develop and commercialize transplant products, indicating a significant reliance on Bio-Rad for ongoing operations [298]. Capital and Financing - The company completed a private placement in February 2025, raising approximately $28.7 million in net proceeds [272]. - The February 2025 Offering generated approximately $29.1 million in gross proceeds, with net proceeds of about $28.7 million after expenses [294]. - Cash flow from financing activities for the year ended December 31, 2025, was $28.1 million, primarily from the February 2025 Offering [307]. - The February 2026 Offering resulted in gross proceeds of approximately $26.0 million, yielding net proceeds of around $24.6 million for general corporate purposes and R&D [295]. Asset and Impairment - Impairment losses on in-process research and development intangible assets totaled $14.6 million in 2025, compared to $41.9 million in 2024 [280]. - A total impairment of $14.6 million was recorded for in-process research and development intangible assets during the year ended December 31, 2025 [317]. - The company recognized an impairment loss on held for sale assets of $169,000 during the year ended December 31, 2024, with no impairments recorded in 2025 [318]. Operational Changes - The company changed its name to Insight Molecular Diagnostics Inc. and relocated its headquarters to Nashville, Tennessee, in June 2025 [273]. - The company acquired a total of 32 new lab instruments for transplant operations by December 31, 2025, compared to seven new instruments as of December 31, 2024 [300]. - The company has a secondary strategic market focus in oncology, although it does not intend to commercialize oncology tests in the next 12 months [269]. Credit and Allowances - As of December 31, 2025 and 2024, the allowance for credit losses related to Laboratory Services was $11,000 and $16,000, respectively [320]. - Total stock-based compensation recognized was $2.2 million for the year ended December 31, 2025, compared to $1.8 million for 2024 [321].

Financial Performance - The company reported a net loss of $161.3 million for the year ended December 31, 2025, compared to a net loss of $127.5 million for the year ended December 31, 2024, with an accumulated deficit of $424.8 million as of December 31, 2025[287]. - The company expects to continue incurring significant losses for the foreseeable future as it invests heavily in research and development[287]. - The company has incurred substantial losses and does not expect to become profitable in the near future, which could adversely affect its financial condition[330]. - The company will incur significant increased costs due to compliance with public company regulations, impacting financial condition and operational focus[302]. - Changes in tax laws, including the potential impact of the Inflation Reduction Act, could materially affect the company's financial performance and tax obligations[331]. Capital Requirements - The company anticipates substantial additional capital will be required to finance operations, including further clinical trials and regulatory approvals for product candidates[292]. - The company may need to delay, reduce, or eliminate research and drug development programs if it cannot raise necessary capital[292]. - The company anticipates that delays relative to projected timelines may require raising additional capital sooner than expected[376]. Regulatory and Approval Challenges - The regulatory approval processes for product candidates are lengthy and unpredictable, which could delay commercialization efforts[297]. - The company has not yet obtained regulatory approval for any product candidates, which poses a risk to its future business prospects[471]. - Changes in regulatory requirements during the clinical development process could lead to additional studies being required, delaying approval timelines[472]. - The FDA may require additional preclinical studies or clinical trials as a condition of approval, potentially delaying the approval timeline[477]. - The FDA is investigating serious risks of T-cell malignancy associated with BCMA-directed and CD19-directed CAR T-cell therapies, which may impact the approval process for new product candidates[476]. Competition and Market Risks - The company faces competition from established pharmaceutical and biotechnology companies that have already developed approved therapies in similar indications[286]. - The company faces intense competition for qualified personnel in the biotechnology sector, particularly in the San Francisco Bay Area, which could hinder its ability to attract and retain necessary staff[325]. - The company faces competition from larger pharmaceutical and biotechnology firms with established therapies, which may hinder market penetration for its product candidates[370]. - Future product candidates may not achieve broad market acceptance, limiting revenue generation and profitability[312]. Clinical Development Risks - Clinical development is lengthy and expensive, with a high risk of failure for product candidates currently in preclinical or clinical stages[352]. - Participant withdrawals from clinical trials may compromise data quality and impact the ability to advance product candidates[355]. - Clinical trial delays may arise from various factors, including regulatory holds, insufficient patient enrollment, and increased costs, potentially impacting the commercialization timeline of product candidates[356]. - The company has not successfully completed any large-scale clinical trials and may face challenges in obtaining regulatory approvals for its product candidates[343]. Intellectual Property Risks - The company relies on intellectual property licensed from third parties, and termination of these licenses could result in significant rights loss, adversely affecting business operations[398]. - Patent protection is essential for the company's product candidates, and failure to obtain or maintain such protection could adversely affect competitive positioning and financial results[404]. - The company may face challenges in patent rights that could result in loss of exclusivity or invalidation of claims, adversely affecting its market position[411]. - The company is aware of third-party patents related to CAR T cells that may impact its product candidates, and there is a risk of infringement claims[438]. Operational Risks - The company relies on third-party manufacturers and suppliers, and any failure in compliance or supply could adversely affect operations[286]. - The company must manage relationships with contract manufacturers and suppliers to ensure product availability and quality[303]. - The company is ultimately responsible for compliance with manufacturing requirements, and failures could lead to regulatory enforcement actions, including fines and penalties[396]. - The company relies on third-party contract manufacturers (CMOs) for cell therapy products, with agreements in place for services through 2026, but future availability of clinical-grade vectors is uncertain[392][393]. Legal and Compliance Risks - Material weaknesses in internal control over financial reporting were previously identified and remediated, but future weaknesses could adversely affect investor confidence and stock value[305]. - The company is required to maintain effective internal controls, and failure to do so could lead to regulatory investigations and penalties[311]. - A shareholder class action complaint was filed against the company and its officers, alleging material misstatements in the IPO registration statement[339]. - The company believes it has substantial defenses against the claims but cannot determine potential losses, thus no loss has been accrued in financial statements for the year ended December 31, 2025[342]. Workforce and Management - The company has 134 full-time employees as of December 31, 2025, and plans to expand its workforce to support development and commercialization efforts[321]. - The company is highly dependent on its Chief Executive Officer and senior management team, and the loss of any key personnel could delay product development and commercialization efforts[324]. Environmental and Safety Compliance - The company may incur substantial costs to comply with environmental, health, and safety laws, which could adversely affect its business operations[466]. - The acceptance of clinical trial data from studies conducted outside the United States by the FDA is uncertain, potentially requiring additional costly trials[468].

Financial Performance - Spero reported a net income of $31.5 million for Q4 2025, compared to a net loss of $(20.9) million in Q4 2024, representing a significant turnaround [10]. - Total revenue for Q4 2025 was $41.3 million, up from $15.0 million in Q4 2024, primarily driven by increased collaboration revenue from agreements with GSK and Pfizer [10]. - Total revenue for the year ended December 31, 2025, was $66.8 million, compared to $48.0 million in 2024, reflecting a year-over-year increase of 39.2% [10]. - Spero received a $25 million milestone payment from GSK in Q1 2026 related to the NDA resubmission [10]. - Total liabilities decreased to $9.9 million as of December 31, 2025, from $64.4 million in 2024, indicating improved financial health [15]. Expenses - Research and development expenses decreased to $5.6 million in Q4 2025 from $28.8 million in Q4 2024, reflecting reduced clinical trial activity [10]. - General and administrative expenses for Q4 2025 were $4.3 million, down from $7.1 million in Q4 2024, due to lower legal and personnel-related costs [10]. Cash Position - As of December 31, 2025, Spero had cash and cash equivalents of $40.3 million, sufficient to fund operations into 2028 [10]. Regulatory and Clinical Updates - The NDA for tebipenem HBr was resubmitted to the FDA in December 2025, with a PDUFA date set for June 18, 2026 [5]. - The Phase 3 PIVOT-PO trial for tebipenem HBr demonstrated non-inferiority to intravenous imipenem-cilastatin, with results presented at IDWeek 2025 [5].

Financial Performance - Consolidated net sales for Q4 fiscal 2025 were $374 million, a decrease of 4% from $391 million in Q4 fiscal 2024[3] - Full fiscal year 2025 consolidated net sales decreased 3% to $1.48 billion compared to $1.52 billion in fiscal 2024[4] - Loss per share on a GAAP basis for fiscal 2025 was $1.86, compared to EPS of $5.87 in fiscal 2024[4] - Adjusted EPS for fiscal 2025 was $2.11, down from $6.68 in fiscal 2024[4] - Tommy Bahama's Q4 sales were $229.2 million, a 4% decline from $237.6 million in Q4 fiscal 2024[7] - Net loss for Q4 Fiscal 2025 was $(7.1) million, translating to a loss per share of $(0.48), compared to net earnings of $17.9 million and earnings per share of $1.14 in Q4 Fiscal 2024[33] - Net earnings for Fiscal 2025 were $(27.9) million, a decrease of 130.0% compared to $93.0 million in Fiscal 2024[35] - Total net sales for Fiscal 2025 were $1,477.8 million, down 2.6% from $1,516.6 million in Fiscal 2024[37] - Operating income for Fiscal 2025 was $(31.3) million, a decrease of 126.3% from $119.0 million in Fiscal 2024[37] - Consolidated net sales decreased by 4.1% to $374.5 million in Q4 2025, and by 2.6% to $1,477.8 million for the full year[39] - Net earnings (loss) for the consolidated entity was a loss of $1.4 million in Q4 2025, a decline of 106.4%, and a full-year net earnings of $31.8 million, down 70.0%[39] Guidance and Expectations - The company expects fiscal 2026 revenues between $1.475 billion and $1.530 billion, with GAAP EPS guidance of $1.83 to $2.43[6] - For Q1 fiscal 2026, net sales are expected to be between $385 million and $395 million, compared to $393 million in Q1 fiscal 2025[18] - The company expects GAAP net earnings per diluted share for Q1 Fiscal 2026 to be between $1.13 and $1.23, compared to $1.70 in Q1 Fiscal 2025[40] - The guidance for Fiscal 2026 indicates a GAAP net earnings per diluted share range of $1.83 to $2.43, compared to $(1.86) in Fiscal 2025[40] - Adjusted net earnings per diluted share for Fiscal 2025 was $2.11, with guidance for Fiscal 2026 set between $2.10 and $2.70[40] Cost and Expenses - Gross margin for fiscal 2025 was 60.7%, down from 62.9% in the prior year, primarily due to increased costs from tariffs[9] - SG&A expenses for fiscal 2025 were $818 million, an increase from $787 million in the prior year[12] - SG&A expenses for Q4 Fiscal 2025 were $207.1 million, up from $202.6 million in Q4 Fiscal 2024[33] - SG&A expenses increased by 3.9% to $817.9 million in Fiscal 2025 from $787.0 million in Fiscal 2024[37] - SG&A expenses increased by 2.5% to $206.2 million in Q4 2025, representing 55.1% of net sales[39] Asset and Debt Management - Total current assets as of January 31, 2026, were $292.4 million, slightly down from $292.8 million as of February 1, 2025[31] - Long-term debt increased to $116.4 million in January 2026 from $31.1 million in February 2025[31] Segment Performance - Segment EBITDA for Tommy Bahama decreased by 35.3% to $94.6 million in Fiscal 2025 from $146.3 million in Fiscal 2024[37] - Tommy Bahama segment EBITDA decreased by 42.2% to $23.6 million in Q4 2025, and by 35.3% to $94.6 million for the full year[38] - Lilly Pulitzer segment EBITDA fell by 51.5% to $3.7 million in Q4 2025, and by 10.3% to $52.1 million for the full year[38] - Johnny Was reported a segment EBITDA loss of $5.7 million in Q4 2025, a decline of 1204.2%, and a full-year loss of $8.5 million, down 213.4%[38] Operational Challenges - The company is facing risks related to inflationary pressures, supply chain constraints, and changing consumer shopping patterns[25][26] - Future performance is subject to various uncertainties, including geopolitical risks and potential changes in U.S. trade policies[25][29] Other Financial Metrics - Cash provided by operating activities was $119.6 million in Fiscal 2025, down from $194.0 million in Fiscal 2024[35] - Cash used in investing activities was $(108.4) million in Fiscal 2025, compared to $(143.3) million in Fiscal 2024[35] - Interest expense increased by 118.5% to $2.0 million in Q4 2025, and by 178.4% to $6.9 million for the full year[38] - The company reported an impairment charge of $60.98 million related to goodwill and intangible assets during Fiscal 2025[33] Store Count and Retail Presence - The total number of Tommy Bahama full-price retail stores was 106 at the end of Q4 Fiscal 2025, unchanged from Q3[42] - The total number of Johnny Was full-price retail stores remained at 77 at the end of Q4 Fiscal 2025[42] - The company reported a total of 345 retail locations across its brands at the end of Q4 Fiscal 2025, an increase from 342 in Q3[42] Changes in Reporting - Segment EBITDA was introduced as a new profit margin measure in Q4 Fiscal 2025, excluding infrequent operating charges[43] - The company revised the presentation of depreciation and amortization expense starting Q4 Fiscal 2025, separating it from SG&A[44]

Earnings Release - ICF International, Inc. will release its Q4 and full year 2025 earnings results on February 26, 2026[7] Conference Call - A conference call to discuss the quarterly results is scheduled for 4:30 p.m. Eastern Time on the same day[7]

Business Operations - BTCS operates as a blockchain technology company focused on revenue generation through Ethereum-based infrastructure and decentralized finance activities [14]. - The company has three primary business lines: Validator Node Operations, Block Building (Builder+), and Decentralized Finance Operations (Imperium) [16][19]. - In 2025, BTCS launched Imperium, which deploys digital assets into DeFi protocols, with revenues dependent on market conditions and protocol utilization [19][20]. - BTCS completed a strategic repositioning in 2025, focusing solely on Ethereum activities and liquidating most non-Ethereum digital asset holdings [22]. - The company expects DeFi revenues to contribute a growing percentage of total revenue in 2026 and beyond, enhancing its integrated position within the Ethereum ecosystem [35][34]. - BTCS's capital strategy combines decentralized finance mechanisms with traditional capital markets activities, utilizing tools like at-the-market equity offerings and ETH-backed DeFi borrowing [24]. - The company aims to expand its Builder+ operations and improve block-building efficiency to drive revenue growth [32]. - The company's blockchain infrastructure activities, including validator node operations and block building, are key revenue drivers, with block building emerging as a higher-growth opportunity [105]. - In 2025, BTCS launched Imperium, a DeFi-focused segment aimed at deploying digital assets into decentralized protocols, enhancing capital flexibility and risk-adjusted returns [108]. - Management expects continued expansion of Builder+ operations and increased deployment through Imperium to create long-term shareholder value [113]. Financial Performance - Total revenues for Fiscal 2025 reached $16,491,584, a 305% increase from $4,073,518 in Fiscal 2024 [138]. - Blockchain infrastructure revenues accounted for $15,177,667, representing a 273% increase from $4,073,518 in the previous year [138]. - Builder+ operations contributed approximately 80% of total revenue, with NodeOps at 12% and Imperium DeFi at 8% [140]. - Total cost of revenues increased to $14,481,654, a 363% rise from $3,127,509 in Fiscal 2024 [138]. - Gross profit for Fiscal 2025 was $2,009,930, reflecting a 112% increase from $946,009 in Fiscal 2024 [138]. - Operating expenses surged to $31,902,502, a 1,356% increase from $2,191,033 in the prior year [138]. - Net loss for Fiscal 2025 was $33,353,433, a 2,524% increase from $1,271,174 in Fiscal 2024 [138]. - Interest expense rose to $3,517,671, a 100% increase compared to the previous year [157]. Shareholder Actions - The Company declared a special dividend of $0.05 per share on its common stock and Series V Preferred Stock during fiscal year 2025, with the dividend paid in October 2025 [93]. - A one-time loyalty payment of $0.35 per share was authorized, payable solely in ETH, to eligible holders of common stock in February 2026 [94]. - The Board approved a share repurchase program authorizing the Company to repurchase up to $50 million of its common stock over a three-year period [96]. - The last reported sale price of the Company's common stock on March 22, 2026, was $1.55 [91]. - The Company has 234 stockholders of record as of March 22, 2026 [92]. - In the quarter ended December 31, 2025, the company purchased a total of 236,657 shares at an average price of $4.16 per share, with a remaining dollar value of $46 million under the publicly announced program [97]. - The company issued 14,205 shares of restricted stock to non-employee directors as compensation for services on December 31, 2025, totaling 64,017 shares issued throughout 2025 [99]. - The Company repurchased and retired 888,677 shares of common stock for approximately $4,000,000 from September 11, 2025, to March 22, 2026, with $46,000,000 remaining available for future repurchases [172][173]. Risk Management and Compliance - The Company prioritizes secure self-custody of digital assets, maintaining internal controls to minimize exposure to third-party risks [26][30]. - The Company has established a comprehensive cybersecurity risk management program to address various cyber threats [72]. - The evolving regulatory environment for digital assets may impose significant costs and operational constraints on the company, affecting its business and financial condition [135]. - Revenues from DeFi activities through Imperium are variable and depend on market conditions, protocol utilization, and liquidity, exposing the company to specific risks [109][133]. Capital and Financing Activities - The Company entered into a new Form S-3 registration statement for up to $2,000,000,000 of securities for future issuance [169]. - The Company borrowed approximately $123,477,000 in stablecoins through Aave, repaying approximately $79,669,000, leaving $43,965,000 in outstanding DeFi borrowings as of March 22, 2026 [174][176]. - The variable borrowing rates on Aave for USDT and GHO were approximately 3.04% and 3.05% per annum, respectively, as of March 22, 2026 [175]. - The Company completed private placements of Senior Secured Convertible Notes totaling approximately $17,861,000 in May and July 2025, with net cash proceeds of approximately $16,844,000 [177][178]. - Cash used in operating activities was approximately $9,784,000 for Fiscal 2025, an increase from approximately $3,530,000 in Fiscal 2024, reflecting expanded operations [189]. - Net cash used in investing activities was approximately $197,497,000 during Fiscal 2025, primarily for the purchase of approximately $201,348,000 of digital assets [192]. - Cash provided by financing activities was approximately $206,830,000 during Fiscal 2025, driven by net proceeds of approximately $135,161,000 from common stock sales under the ATM equity program [194][195]. - As of March 22, 2026, the Company had total debt obligations of approximately $61,826,000, including $43,965,000 under the Aave lending arrangement [186]. - The Company anticipates future financing activities may include additional DeFi borrowings and capital raised through the ATM program to support long-term growth [197]. - As of March 22, 2026, the fair market value of the Company's liquid digital assets was approximately $118,951,000 [185]. - The company actively monitors collateralization ratios and market movements, adjusting borrowings based on market conditions and risk tolerance [212]. Employee and Governance - The Company is committed to fostering an engaged workforce through a culture of accountability and professional development [64]. - The Compensation Committee oversees executive compensation and succession planning, ensuring competitive compensation arrangements [65]. - Stock-based compensation is accounted for under ASC 718, with expenses measured at fair value on the grant date and recognized over the requisite service period [213].